XERS Xeris Pharmaceuticals Inc.

11.59
+0.78  (+7%)
Previous Close 10.81
Open 10.92
Price To Book 4.18
Market Cap 312,783,398
Shares 26,987,351
Volume 117,952
Short Ratio
Av. Daily Volume 203,031

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2a data due 2H 2019.
Continuous glucagon
Hypoglycemia-Associated Autonomic Failure
Phase 3 trial to be initiated 2H 2019.
Continuous glucagon
Congenital Hyperinsulinism
Phase 2 data due 2H 2019.
Self administered glucagon
Exercise-Induced Hypoglycemia
Phase 2b data due 2H 2019.
Self administered glucagon
Post-Bariatric Hypoglycemia
PDUFA date extended by three months to September 10, 2019.
Glucagon Rescue Pen
Severe hypoglycemia
Phase 2 trial to be initiated 2H 2019.
Diazepam
Seizures

Latest News

  1. Xeris Pharmaceuticals, Inc. (XERS) Reports Q2 Loss, Tops Revenue Estimates
  2. Xeris Pharmaceuticals Announces Second Quarter 2019 Financial Results and Highlights
  3. Xeris Pharmaceuticals, Inc. (XERS) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
  4. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
  5. Did Changing Sentiment Drive Xeris Pharmaceuticals's (NASDAQ:XERS) Share Price Down By 38%?
  6. Xeris Pharmaceuticals Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
  7. Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Developmental Ready-to-use Glucagon in Patients at Risk From Hypoglycemia Following Bariatric Surgery
  8. Xeris Pharmaceuticals Announces Additional Positive Outcomes from a Global Phase 3 Clinical Trial of Its Investigational Ready-to-Use Glucagon
  9. Can We See Significant Institutional Ownership On The Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Share Register?
  10. Xeris Pharmaceuticals Announces First Quarter 2019 Financial Results and Highlights Its Pipeline
  11. Xeris Pharmaceuticals Announces Results From a Phase 1 Study of Its Novel Formulation of Diazepam
  12. Xeris Pharmaceuticals Presents New Clinical and Economic Impact Data on Its Developmental Ready-to-Use Glucagon
  13. Xeris Pharmaceuticals Doses First Patient in Phase 2 Trial Evaluating Its Ready-to-Use Glucagon to Address Exercise-Induced Hypoglycemia
  14. How Many Insiders Bought Xeris Pharmaceuticals, Inc. (NASDAQ:XERS) Shares?
  15. Xeris Pharmaceuticals Announces Fourth Quarter and Full Year 2018 Financial Results and Highlights Pipeline Progress
  16. Xeris Pharmaceuticals Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
  17. Xeris Pharmaceuticals to Participate at SVB Leerink Global Healthcare Conference
  18. Xeris Pharmaceuticals Announces Pricing of Public Offering of Shares of Common Stock